Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 tablets plus azacitidine in myeloid malignancies (Ib/II)
CTR20240365Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Nanjing Shunxin Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
TQB3909
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20240365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240365.